Objectives: In this study we investigated if CP
induced ototoxicity could be prevented or reduced
by the use of salicylate and N-acetylcysteine.
Patients and Methods: Fifty-four patients (28
females, 26 males; mean age 37±9.5 years; range
29 to 71 years) who had cisplatin chemotherapy due
to solid organ tumors were enrolled in the study. The
patients were randomized into three groups, with
18 patients in each group. The first group (control
group) received cisplatin, second group received
N-acetylcysteine (NAC; 600 mg/day) with cisplatin
and the third group received salicylate (300 mg/day)
with cisplatin. All patients evaluated audiologically
including high frequency audiometry and auditory
Results: The cisplatin-induced ototoxic damage
could be reduced in 10,000 and 12,000 Hz frequencies
when N-acetylcysteine was added to the cisplatin
therapy protocol. There was no decrease in the
hearing loss levels of the patients who were receiving
cisplatin with salicylate.
Conclusion: According to auditory brainstem
response testing results, there was no difference
detected between N-acetylcysteine or salicylate for
the amelioration of cisplatin induced ototoxicity.
FREE FULL TEXTAnahtar Kelimeler: Cisplatin; N-asetilsistein; ototoksisite;salisilat.